FY2020 EPS Estimates for Tabula Rasa HealthCare Inc Reduced by Analyst (NASDAQ:TRHC)
Tabula Rasa HealthCare Inc (NASDAQ:TRHC) – Investment analysts at Cantor Fitzgerald reduced their FY2020 earnings per share (EPS) estimates for shares of Tabula Rasa HealthCare in a report released on Thursday, June 25th. Cantor Fitzgerald analyst S. Halper now forecasts that the company will post earnings of ($0.37) per share for the year, down from their prior forecast of ($0.25). Cantor Fitzgerald has a “Overweight” rating and a $83.00 price objective on the stock.
Other research analysts have also recently issued research reports about the stock. ValuEngine cut shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Tuesday, May 12th. Benchmark cut their price target on shares of Tabula Rasa HealthCare from $90.00 to $84.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Royal Bank of Canada initiated coverage on shares of Tabula Rasa HealthCare in a research note on Monday, April 20th. They issued an “outperform” rating and a $70.00 price target on the stock. SVB Leerink initiated coverage on shares of Tabula Rasa HealthCare in a research note on Monday, April 13th. They issued an “outperform” rating and a $65.00 price target on the stock. Finally, BidaskClub lowered shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Tuesday, May 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $68.60.
Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.24. The firm had revenue of $72.80 million during the quarter, compared to analysts’ expectations of $71.76 million. Tabula Rasa HealthCare had a negative net margin of 12.10% and a negative return on equity of 3.01%. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 earnings per share.
In other news, President Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $58.81, for a total value of $470,480.00. Following the sale, the president now owns 741,756 shares of the company’s stock, valued at $43,622,670.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gordon Tunstall sold 1,000 shares of the company’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the director now directly owns 12,989 shares in the company, valued at $649,450. The disclosure for this sale can be found here. In the last three months, insiders sold 67,040 shares of company stock worth $3,919,268. 11.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of TRHC. Meeder Asset Management Inc. bought a new stake in Tabula Rasa HealthCare during the fourth quarter worth $39,000. Orion Portfolio Solutions LLC bought a new position in shares of Tabula Rasa HealthCare in the fourth quarter worth about $39,000. Rockefeller Capital Management L.P. bought a new position in shares of Tabula Rasa HealthCare in the fourth quarter worth about $44,000. US Bancorp DE lifted its holdings in shares of Tabula Rasa HealthCare by 13.0% in the first quarter. US Bancorp DE now owns 2,560 shares of the company’s stock worth $133,000 after acquiring an additional 295 shares during the last quarter. Finally, Advisor Group Holdings Inc. bought a new position in shares of Tabula Rasa HealthCare in the first quarter worth about $146,000.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Featured Article: Risk Tolerance
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.